Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge
Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented today by Sam Lee, Ph.D., President and co-CEO, at the 7th Annual
Cocrystal Pharma, Inc. (NASDAQ:COCP) (Cocrystal or the Company) announces the acceptance of an oral presentation containing new data from the Company's CC-42344 Phase 1 influenza A study at the 7th Annual
The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.